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Background: Insulin is tightly associated with cancer progression; however, mechanistic insights into such
observations are poorly understood. Recent studies show that metabolic transformation is critical to cancer cell
proliferation. Here, we attempt to understand the role of insulin in promotion of cancer metabolism. To this end,
the role of insulin in regulating glycolytic enzyme pyruvate kinase M2 (PKM2) was examined.
Results: We observed that insulin up-regulated PKM2 expression, through PI3K/mTOR mediated HIF1α induction,
but significantly reduced PKM2 activity independent of this pathway. Drop in PKM2 activity was attributed to
subunit dissociation leading to formation of low activity PKM2 oligomers, as assessed by density gradient
centrifugation. However, tyrosine 105 phosphorylation of PKM2, known for inhibiting PKM2 activity, remained
unaffected on insulin treatment. Interestingly, insulin-induced ROS was found responsible for PKM2 activity
reduction. The observed changes in PKM2 status led to augmented cancer metabolism. Insulin-induced PKM2
up-regulation resulted in enhanced aerobic glycolysis as confirmed by PKM2 knockdown studies. Further, PKM2
activity reduction led to characteristic pooling of glycolytic intermediates and increased accumulation of NADPH;
suggesting diversion of glucose flux towards macromolecular synthesis, necessary for cancer cell growth.
Conclusion: The study identifies new PKM2-mediated effects of insulin on cancer metabolism, thus, advancing the
understanding of insulin’s role in cancer.
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Cancer cell metabolism differs from that of normal cells
and is characterized by high glucose uptake and lactate
production even in presence of sufficient oxygen, an
observation made by Otto Warburg in 1920’s. The
phenomenon has been referred to as Warburg effect
or aerobic glycolysis [1] which forms the basis of
18fluorodeoxyglucose-positron emission tomography
(FDG-PET) – a diagnostic technique used for clinical
detection of cancer [2]. Although, inefficient in terms of
ATP production, aerobic glycolysis, nonetheless, is vital
to maintain macromolecule synthesis needed to produce
daughter cells [3]. Further, aerobic glycolysis is believed
to provide cancer cells a selective advantage to grow in* Correspondence: bame0200@mail.jnu.ac.in
National Centre of Applied Human Genetics, School of Life Sciences,
Jawaharlal Nehru University, New Delhi 110067, India
© 2013 Iqbal et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orregions with low oxygen concentration [4]. Considering
the significance of aerobic glycolysis to cancer cells,
metabolic behaviour is now perceived as a critical target
for anti-cancer therapeutics [5,6]. Among the several
glycolytic genes that are up-regulated in cancer [7],
pyruvate kinase is of prime significance because of its
key position in glycolytic sequence [8,9]. It catalyzes the
last step of glycolysis i.e. conversion of phosphoenolpyr-
uvate (PEP) to pyruvate with concomitant ATP produc-
tion [10]. Out of four isoforms of pyruvate kinase (PK)
in mammals- L, R, M1 and M2 [11]; tumor cells pre-
dominantly express M2 isoform [11]. Switch to this iso-
form is considered essential for aerobic glycolysis and
tumor growth [12].
Activity of PKM2 is critical to determine a shift in me-
tabolism required for tumor growth. Decrease in PKM2
activity causes pooling of glycolytic intermediates whichd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 PKM2 is the major isoform in HepG2 cells. Immunoblot
showing that PKM2 expression is many-fold higher than other PK
isoforms in hepatoma cells. PKL, which is typically present in normal
liver cells, is expressed at very low levels in cancerous HepG2 cell
line. M1, which is present in energy requiring tissues such as brain
and muscle, is completely absent in HepG2 cells. L6 cell line (rat
skeletal muscle) is used as a positive control for M1 and a negative
control for PKL isoform.
Iqbal et al. Molecular Cancer 2013, 12:72 Page 2 of 12
http://www.molecular-cancer.com/content/12/1/72are then shunted to pentose phosphate pathway (PPP) for
NADPH generation for macromolecular synthesis, essen-
tial for cellular growth [8,9,11,13]. Therefore, decreased
PKM2 activity is believed to favour rapidly proliferating
cancer cells; however, the phenomenology of PKM2 activ-
ity regulation by external factors is not well understood.
PKM2 exists in highly active (tetramer) and less active
(dimer/monomer) oligomeric forms. The ratio of these
forms decides the overall PKM2 activity in cellular milieu
[11,14,15]. In cancer cells, disruption of active PKM2 tet-
ramers results in accumulation of less active PKM2 mono-
mers/dimers, thus, promoting anabolic synthesis [9,13].
Our previous work has shown how two missense muta-
tions in PKM2 stabilized less active PKM2 form to pro-
mote cellular growth and polyploidy [16].
Evidences in recent years have suggested a crucial role of
insulin in cancer cell growth and survival [17-20]. High
levels of endogenous insulin among type-2 diabetics and
non-diabetics have also been associated with increased can-
cer risk in epidemiological studies [21]; with highest risk for
liver and pancreatic cancer [22-24]. Significantly, insulin re-
ceptor has been reported to provide resistance to IGF-1R
targeted therapies [25]; emphasizing the importance of
targeting insulin signalling. The role of insulin, however, in
regulation of cancer cell metabolism is still obscure.
In this study, the role of insulin in promotion of can-
cer metabolism is examined. We show that insulin
promotes cancer metabolism by upregulating PKM2 ex-
pression and decreasing its activity. Insulin-induced
changes in PKM2 status directly resulted in amplifica-
tion of cancer-metabolism-specific parameters like glu-
cose uptake, lactate production, glycolytic pooling and
macromolecular synthesis. Our results contribute to bet-
ter understanding of the role of insulin in cancer metab-
olism and thus cancer progression.
Results
PKM2 is the predominant isoform of pyruvate kinase
in cancer cells
PK exists in four isoforms in mammals; therefore, isoform
status of PK in HepG2, H1299 and PC3 cells was exam-
ined. Immunoblotting analysis in HepG2 showed that
PKM2 was the predominant isoform in these cells with
complete absence of PKM1 (Figure 1). Whereas, PKL
isoform, which is predominant in normal liver cells,
expressed at a much lower level in HepG2 cells (Figure 1).
Similarly, PKM2 was the predominant isoform in
H1299 and PC3 cells with negligible PKM1 expression
(Additional file 1: Figure S1).
Insulin upregulates PKM2 expression in a PI3K/mTOR
dependent manner by inducing HIF1α expression
To examine the effect of insulin on PKM2 expression,
serum starved HepG2 cells were treated with insulin for0, 2, 4, 6 and 8 hours with maximum increase in PKM2
expression at 8 hours of insulin treatment (Figure 2A).
Dose dependent effect of insulin on PKM2 expression
Figure 2 Insulin increased PKM2 expression via HIF1α up-regulation, in a PI3K/mTOR dependent manner. (A) Serum starved HepG2 cells
were treated with 100 nM insulin for 0–8 hours, maximum increase in PKM2 protein observed after 8 hours of 100 nM treatment. (B) Dose
dependent increase in PKM2 expression. (C) Total RNA and protein was extracted and subjected to real time PCR and immunoblotting
respectively, PKM2 mRNA increased by ~2 fold in a PI3K/mTOR dependent manner (as LY294002 and rapamycin decreased PKM2 mRNA). For
PI3K/mTOR inhibition, cells were pretreated with 50 μM LY294002 or 20 nM rapamycin for 30 minutes before stimulating cells with insulin. (D)
Representative immunoblot showing insulin-induced up-regulation of PKM2 and its transcriptional regulator HIF1α in a PI3K/mTOR sensitive
manner. However, PKL expression remained unchanged on insulin treatment. For PI3K/mTOR inhibition, cells were pretreated with 50 μM
LY294002 or 20 nM rapamycin for 30 minutes. (E) Densitometric analysis was done using Alpha Imager EP densitometer (Alpha Innotech Corp.,
USA). (F) CoCl2 treatment (100 μM for 8 hours) resulted in accumulation of HIF1α with concomitant increase in PKM2 expression, siRNA mediated
HIF1α silencing resulted in decreased PKM2 expression. These results suggest that insulin promoted PKM2 expression through HIF1α induction, in
a PI3K/mTOR dependent manner. β actin was used as endogenous control in real time experiments and loading control in immunoblotting.
mRNA data is expressed as mean ± SE. *P ≤ 0.05.
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tration) substantially induced PKM2 expression, how-
ever, maximum increase in PKM2 expression was
observed with 100 nM insulin for 8 hours (Figure 2B);
suggesting to choose 100 nM insulin for further experi-
ments. A two fold increase in PKM2 mRNA and protein
expression was observed upon 100 nM insulin treatment
for 8 hours (Figure 2C-E), whereas, PKL expression
remained unaltered under similar conditions (Figure 2D).
Insulin treatment up-regulated PKM2 in H1299 (lung
cancer) and PC3 (prostate cancer) cells also (Additional
file 2: Figure S2), replicating the observations made in
HepG2 cells.
PI3K/mTOR signalling was inhibited to find out if
insulin-induced PKM2 up-regulation is PI3K dependent.PI3K is the chief mediator of insulin signalling in liver
and is frequently mutated in liver and other cancers
[26-28]. As a result of PI3K/mTOR inhibition, PKM2 ex-
pression was down-regulated (Figure 2C-E). These re-
sults confirmed that insulin regulates PKM2 expression
through PI3K/mTOR pathway. To elucidate how PI3K/
mTOR promoted PKM2 expression, the role of HIF1α
protein, a transcription factor that binds to hypoxia re-
sponse element (HRE) in PKM2 gene to induce its ex-
pression, was examined [29,30]. Insulin induced HIF1α
expression in a PI3K/mTOR sensitive manner, as was
evident from the decrease in HIF1α protein after treat-
ment with PI3K/mTOR inhibitors (Figure 2D). Further,
to corroborate this observation, HIF1α was silenced as
well as induced, using siRNA and cobalt chloride
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PKM2 expression [31,32]. Expectedly, HIF1α silencing
led to a decreased PKM2 expression; whereas CoCl2-in-
duced HIF1α accumulation increased PKM2 expression
(Figure 2F), confirming that HIF1α is crucial for PKM2
up-regulation. These results demonstrated that insulin
upregulates PKM2 expression through PI3K/mTOR
dependent induction of HIF1α transcription factor.
Insulin inhibits PKM2 activity, in a PI3K/mTOR
independent manner, by promoting subunit dissociation
PKM2 activity is crucial in determining the glycolytic
flux; it was pertinent therefore to examine the potential
role of insulin in altering PKM2 activity. Interestingly,
~30% drop in PKM2 activity was observed in HepG2Figure 3 PKM2 activity decreased as a result of subunit dissociation u
100 nM insulin treatment of 15 minutes reduced PKM2 activity in HepG2 c
LY294002 or 20 nM rapamycin for 30 minutes) did not significantly alter PK
used to monitor decrease in OD due to oxidation of NADH at 340 nm. (B)
oligomeric forms of PKM2. Activity was assessed in different fractions to de
concomitant fall in peak II is suggestive of disruption of highly oligomerise
corresponds to the respective amount of particular oligomeric form. (C) Re
tetrameric PKM2 has optimal activity [15], it can be concluded that PKM2 a
(D) Dose-dependent decrease in PKM2 activity upon insulin treatment. Datcells within 15 minutes after insulin treatment with no
further decrease on increasing the duration of treatment
(Figure 3A, Additional file 3: Figure S3). However, PI3K/
mTOR inhibition did not reverse insulin-induced de-
crease in PKM2 activity (Figure 3A). Insulin-treated
H1299 and PC3 cells also exhibited decrease in PKM2
activity (Additional file 4: Figure S4). To analyse if the
insulin-induced drop in PKM2 activity is due to subunit
dissociation, which governs the overall activity of PKM2
[9,11,15,33,34], glycerol density gradient centrifugation
was performed using HepG2 cell lysate. Density gradient
centrifugation is known to separate different oligomeric
forms of an enzyme with highest quaternary form at the
bottom of the gradient and the magnitude of activity
representing the respective content of an oligomericpon insulin treatment, in a PI3K/mTOR independent manner. (A)
ells by ~30%. Pretreatment with PI3K/mTOR inhibitors (50 μM
M2 activity. For activity measurement: NADH/LDH coupled assay was
Glycerol density gradient centrifugation was used to separate
tect any shift in peaks i.e. subunit dissociation. Rise in peak I with
d PKM2 (tetramer) in less oligomerised forms. Activity in a fraction
lative peak areas show significant shift in peaks I and II. As
ctivity decreased as a result of dissociation of active tetramers.
a is expressed as mean ± SE. *P≤ 0.05.
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lected from top to bottom of the glycerol gradient. Ob-
servation of two peaks suggested two oligomeric forms
of PKM2 and the vertical shift in peaks indicated subunit
dissociation (Figure 3B). As evident from relative peak
areas, a significant fall in peak II with concomitant
increase in peak I, compared to control peaks, was
observed upon insulin treatment (Figure 3C). Dose
dependent insulin treatment showed that even 1nM in-
sulin treatment decreased PKM2 activity significantly
with maximum decrease on 100 nM insulin (Figure 3D).
Results, thus, suggested that decrease in PKM2 activity
was due to subunit dissociation upon insulin treatment.
As expected, PI3K/mTOR inhibition did not abolish the
effect of insulin on PKM2 oligomeric status (Additional
file 5: Figure S5). In an attempt to understand how insu-
lin promoted subunit dissociation, we checked the tyro-
sine 105 phosphorylation of PKM2, which is known to
diminish its activity by disrupting the formation of active
tetramer [33], but, no change in phosphorylation wasFigure 4 Ascorbate or NAC pretreatment decreases insulin induced R
pretreated with 200 μM ascorbate or 5 mM NAC for 1 hour [41], were incu
nM insulin treatment for 15 minutes. DCFH-DA fluorescence was measured
increased ROS production by ~60% as compared to serum starved control
insulin induced ROS. (B) PKM2 activity increased in ascorbate or NAC pretre
increase in ROS production by insulin. (D) PKM2 activity from insulin treate
induced decrease in PKM2 activity by DTT suggests the possibility of oxidaobserved following insulin treatment (Additional file 6:
Figure S6 and Additional file 7: Figure S7). These results
suggested the role of some other insulin-induced factors
in PKM2 activity regulation.
Evidence for the involvement of ROS in inhibition of
PKM2 activity
To find out the factor responsible for inhibition of
PKM2 activity in HepG2 cells, the possible role of
insulin-induced ROS was analysed. ROS is known to
regulate the activity of several proteins through oxida-
tion, we thus investigated if insulin-induced-ROS af-
fected PKM2 activity through its possible oxidation.
Insulin treatment increased the in-vitro production of
ROS by ~60%, as assessed by fluorescence spectropho-
tometry (Figure 4A). Pretreatment with ascorbate (Asc)
or N-acetyl-L-cysteine (NAC), well-known ROS scaven-
gers [36-41], reduced insulin-induced-ROS markedly
by ~50-70%. This observation was replicated in H1299
and PC3 cells (Additional file 8: Figure S8). Interestingly,OS and increases PKM2 activity. (A) Serum starved HepG2 cells,
bated with DCFH-DA for 30 minutes at 37°C (in dark) followed by 100
to assess production of ROS (see Materials and methods). Insulin
. However, ascorbate or NAC pretreatment significantly decreased
ated cells compared to untreated control. (C) Dose dependent
d cells in absence and presence of 1mM DTT. Reversal of insulin-
tion of PKM2 by ROS. Data is expressed as mean ± SE. *P ≤ 0.05.
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with insulin, reversed the insulin-induced decrease in
PKM2 activity in HepG2 (Figure 4B), H1299 and PC3
(Additional file 4: Figure S4) cells, suggesting the role of
insulin-induced-ROS in PKM2 activity inhibition. Fur-
ther, dose-dependent increase in ROS production by in-
sulin correlated with dose-dependent decrease in PKM2
activity (compare Figures 3D and 4C). To understand
how ROS contributed to reduction in PKM2 activity, the
possibility of ROS-induced- oxidation of PKM2 was
studied. Addition of dithiothreitol (DTT), a strong redu-
cing agent, to activity reaction mixture abolished
insulin-induced-decrease in PKM2 activity (Figure 4D).
In fact, addition of DTT increased PKM2 activity to the
levels similar to that of control without insulin treatment
(Figure 4D and B). These data indicated the role ofFigure 5 Insulin promoted aerobic glycolysis, partly, by upregulating
cells was collected for measurement of glucose uptake and lactate production
glucose uptake and lactate production in a PI3K/mTOR sensitive manner. (B) P
(C) Glucose uptake and lactate production decreased on silencing PKM2 in PT
partly, through PKM2 up-regulation. (D) Cellular proliferation decreased on PK
*P≤ 0.05.ROS-induced-oxidation of PKM2 [34], resulting in its
activity-inhibition.
PKM2 up-regulation is crucial in insulin-induced aerobic
glycolysis
PKM2 expression has been suggested to promote aerobic
glycolysis [12,30], which is characterized by high glucose
uptake and lactate production even in presence of oxygen,
and is believed to be the hallmark of nearly all cancer cells
[4]. Both glucose uptake and production of lactate were
substantially enhanced in cells treated with insulin as
compared to untreated control (Figure 5A). Further, inhib-
ition of PI3K/mTOR pathway reduced aerobic glycolysis
which is consistent with earlier reports (Figure 5A)
[42,43]. To show that PI3K/mTOR dependent PKM2 up-
regulation contributed to insulin-induced augmentation inPKM2. Media used by insulin treated (100 nM for 8 hours) or untreated
as described in materials and methods section. (A) Insulin promoted
KM2 knockdown efficiency as checked by real time and Western blotting.
EN negative PC3 cells; indicating that insulin stimulated aerobic glycolysis,
M2 knockdown. C-serum starved cells. Data is expressed as mean ± SE.
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hyperactive PI3K/mTOR signalling (to mimic insulin-
induced activation of PI3K/mTOR), followed by an
assessment of glucose uptake and lactate production,
approximately 48 hours after transfecting control shRNA
or PKM2-shRNA (to knock down PKM2 expression).
Interestingly, silencing of PKM2 partially inhibited glucose
uptake and lactate production, signifying that PKM2 is re-
quired for aerobic glycolysis (Figure 5B-C). Moreover,
PKM2 knockdown also retarded cellular proliferation
(Figure 5D), consistent with our previous observation [44].
Glycolytic intermediates and NADPH accumulated as a
result of decreased PKM2 activity
Characteristic accumulation of glycolytic intermediates,
as a result of decreased PKM2 activity, is another key
feature of cancer cells and has been shown to be import-
ant for anabolic synthesis required for tumor growth
[8,11]. To explore the implications of insulin-induced
suppression of PKM2 activity on glycolytic pooling,
intracellular levels of fructose-1,6-bisphosphate (FBP)
and phosphoenolpyruvate (PEP), the glycolytic metabo-
lites upstream of PKM2, were measured [15]. Conse-
quently, an increased build-up of both metabolites wasFigure 6 Increased glycolytic pooling and NADPH accumulation due
cells were treated with or without 100 nM insulin for 15 minutes or pretrea
200 μM for 30 minutes followed by 100 nM insulin treatment. Intracellular
materials and methods section. (A) Increased accumulation of PEP (~1.7 fo
LY294002 and rapamycin decreased glycolytic pooling modestly, however
pooling of FBP and PEP. (B) NADPH accumulated in insulin treated cells, su
PI3K/mTOR inhibitors decreased NADPH accumulation; however, pretreatm
extent, bringing NADPH levels similar to that of control. These results sugg
mainly by decreasing PKM2 activity, and also indicates the diversion of glu
concentrations is expressed as nmol per million cells. Data is expressed asobserved compared to control (Figure 6A). Glycolytic
pooling is known to facilitate pentose phosphate path-
way for macromolecular synthesis [8,9,13]. Therefore,
intracellular levels of NADPH, which is produced as a
result of PPP and provides reducing power for macro-
molecular synthesis [45], were determined. Accumula-
tion of NADPH increased significantly (P < 0.05) in
insulin treated cells (Figure 6B).
To demonstrate that decreased PKM2 activity is con-
tributing to the observed accumulation of FBP, PEP and
NADPH, PI3K/mTOR pathway was inhibited as it in-
creases glucose uptake which might have contributed to
observed accumulation. PI3K/mTOR inhibition did not
completely block the insulin-induced pooling of FBP,
PEP and NADPH. However, pretreatment with ROS
scavengers NAC or ascorbate abolished the insulin-
induced glycolytic pooling and accumulation of NADPH.
These results indicated that insulin promoted accumula-
tion of glycolytic intermediates and NADPH through de-
creased PKM2 activity.
Discussion
In recent years, PKM2 has emerged as a key regulator of
cancer metabolism. Considering the PKM2-mediatedto insulin-induced PKM2 activity inhibition. Serum starved HepG2
ted with 50 μM LY294002 or 20 nM rapamycin or 5 mM NAC or
PEP, FBP and NADPH were extracted and measured as described in
ld) and FBP (~1.6 fold) was observed in insulin stimulated cells.
ROS scavengers NAC and ascorbate substantially decreased glycolytic
ggesting enhanced anabolic synthesis via PPP [8,9]. Pretreatment with
ent with ROS scavengers reduced NADPH accumulation to greater
est that insulin promoted accumulation of glycolytic intermediates
cose flux towards PPP [8,9]. Actual change in intracellular
mean ± SE. *P≤ 0.05.
Iqbal et al. Molecular Cancer 2013, 12:72 Page 8 of 12
http://www.molecular-cancer.com/content/12/1/72pro-cancerous effects of insulin, our results seemingly
provide a mechanistic understanding into insulin’s role
in cancer metabolism.
The predominance of PKM2 over other PK isoforms
in HepG2, H1299 and PC3 cells (Figure 1 and Additional
file 1: Figure S1) [30,46], indicated the importance of
this PK isoform in cancer, and is consistent with the
notion that switch to PKM2 isoform is required for can-
cer progression [12]. The insulin induced-up- regulation
of PKM2, with evident increase at as low as 1 nM insu-
lin (Figure 2), is an important observation, since PKM2
has been reported essential for aerobic glycolysis and
tumor growth [30]. PI3K-dependence of PKM2 expres-
sion supports the notion that PI3K pathway is central to
insulin signalling in cancer cells and correlates with high
frequency of PI3K mutations in several cancer types,
which may lead to increased expression of PKM2
[26,27]. PI3K/mTOR dependent induction of HIF1α on
insulin treatment, and CoCl2-induced concomitant HIF1
α and PKM2 accumulation, along with HIF1α silencing
results (with decreased PKM2 expression) clearly sug-
gested that insulin promoted PKM2 expression through
HIF1α (Figure 2D and F). Our results are consistent with
previous observations of insulin up-regulation of PKM2
in adipocytes [47] and decreased PKM2 expression on
PI3K/mTOR inhibition [44,48]. These results also ex-
plain the recent observation of high PKM2 in PTEN
(negative regulator of PI3K pathway) null fatty liver cells
[49]. Decreased aerobic glycolysis on PKM2 knock-down
in PTEN deficient (hyper-activated PI3K/mTOR signal-
ling) PC3 cells suggested that insulin promoted aerobic
glycolysis, at least in part, through PKM2 (Figure 5). Im-
portance of PKM2 in aerobic glycolysis could be realized
from the observation that PKM2 transactivates expres-
sion of genes like glucose transporter-1 (GLUT1) and
lactate dehydrogenase-A (LDHA), required for glucose
uptake and lactate production respectively [29]. Appar-
ently, these results present an important mechanism
which may underlie insulin’s role in carcinogenesis.
Decreased PKM2 activity fuels macromolecular syn-
thesis by accumulating glycolytic intermediates that are
precursors for PPP. Suppression of PKM2 activity pre-
sents yet another dimension of insulin’s role in promo-
tion of cancer metabolism. Rise in peak I with
simultaneous fall in peak II suggested subunit dissoci-
ation leading to increased formation of low activity olig-
omeric form of PKM2 (Peak I in Figure 3B), thus
justifying the observed decrease in PKM2 activity
(Figure 3A). Intriguingly, activity of PKM2 was not
affected on PI3K/mTOR inhibition (Figure 3A and
Additional file 6: Figure S5), indicating the involvement of
other factors in activity regulation. Increased PKM2 activity
in ascorbate or NAC pretreated cells suggests the involve-
ment of ROS in activity regulation (Figure 4 and Additionalfile 4: Figure S4). Reversal of insulin-induced decrease in
PKM2 activity by DTT suggests the possibility of ROS-
induced oxidation of cysteine residues in PKM2 [34].
Correlation between dose dependent changes in PKM2
activity and ROS production further support our conclu-
sion of ROS mediated PKM2 activity inhibition (Figures 3D
and 4C). Notably, ROS induced decrease in PKM2 activity
has been linked with ability of lung cancer cells to with-
stand oxidative stress [34]. However, further research is
needed to support this observation in liver and prostate
cancer cells.
The decrease in the activity of PKM2, positioned at
the end of glycolytic sequence, in cancer cells is sug-
gested to accumulate important glycolytic intermediates
required for cellular growth. On the contrary, a decrease
in the activity of enzyme, like hexokinase, which appear
earlier in glycolytic sequence, does not provide the same
advantage to the cancer cells; thus the biosynthetic pro-
cesses required for cellular growth would be inhibited.
Accumulation of glycolytic intermediates PEP and FBP
(Figure 6) indicated the diversion of glucose flux towards
biosynthetic pathway PPP [8], an observation which was
confirmed when PPP product NADPH accumulated
upon insulin treatment (Figure 6B). The decrease in
glycolytic pooling and NADPH accumulation on PI3K/
mTOR inhibition correlated with glucose uptake regula-
tion by PI3K/mTOR pathway (Figures 5A and 6). Inter-
estingly, metabolite accumulation decreased almost to
the levels of untreated control upon treatment with ROS
scavengers NAC or ascorbate, suggesting a crucial role
of decreased PKM2 activity in insulin-induced metabol-
ite build-up. ROS scavenging increased PKM2 activity
which negatively affected metabolite pooling and macro-
molecular synthesis (Figures 4B and 6).
On insulin treatment a maximum PKM2 expression was
observed at 8 hours; whereas a decrease in activity was ob-
served within 15 minutes, which was almost constant till 8
hours. Since no further decrease in activity was observed
by prolonging insulin treatment till 8 hours (Additional
file 3: Figure S3), we chose 15 minutes as the earliest time
point at which PKM2 activity decreased. The up-
regulation of PKM2 expression with concomitant decrease
in activity was associated with enhanced aerobic glycolysis
and increased macromolecular synthesis (Figures 4 and 5).
PKM2 expression is critical for aerobic glycolysis as it
transactivates expression of GLUT1 (glucose transporter)
and LDHA (lactate dehydrogenase) [29]. We have shown
that knockdown of PKM2 expression decreased aerobic
glycolysis (Figure 5C) while inhibition of PKM2 activity
promoted pooling of glycolytic intermediates which are
then shunted to PPP for anabolic synthesis [8,13,33,34].
Apparently, dual regulation of PKM2 expression and ac-
tivity by insulin ensures the promotion of both aerobic
glycolysis and anabolic synthesis, required for cancer cell
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tween high insulin levels and elevated cancer risk. More-
over, reduced PKM2 activity might explain liver cirrhosis
due to fatty liver since PKM2 activity reduction is known
to promote lipid synthesis [13].
Conclusion
Our study highlights previously unknown PKM2-
mediated effects of insulin in promotion of cancer
metabolism, which probably explains the observations of
increased cancer risk under hyperinsulinemic condition
[17,24,50].
Materials and methods
Cell culture, drug treatment, knockdown and proliferation
studies
HepG2 and PC3 cell lines were procured from the Na-
tional Centre for Cell Science, Pune, India. H1299 cells
were a kind gift from Dr. Uttam Pati, School of Biotech-
nology, Jawaharlal Nehru University. All the cell lines
were maintained in DMEM (Sigma) with 10% heat-
inactivated FBS (Biowest, France), 1% penicillin/strepto-
mycin (Sigma) at 37°C and 5% CO2 in a humified
atmosphere (Heraeus, UK). Cells were grown in mono-
layer and passaged routinely two-three times a week. For
drug treatment; LY294002 (Sigma) and rapamycin (Sigma)
were dissolved in DMSO; single use aliquots were stored
at −80°C For insulin treatment: cells were seeded inFigure 7 Graphical summary. Effect of insulin on PKM2 expression
(through PI3K/mTOR/HIF axis) and activity (ROS-dependent),
resulting in amplified cancer metabolism.triplicate at a density of 0.4 million cells/well of six well
plates, serum starved for 20–24 hours and then stimu-
lated with insulin (Sigma) in presence or absence of in-
hibitors. DMSO treated cells were used as mock control.
For PKM2 knockdown: short hairpin RNA (shRNA)
constructs in lentiviral pGIPZ vector were purchased
from Open Biosystems. Control and shRNA containing
pGIPZ vectors were transfected using polymer based
transfection reagent- Arrestin from Thermo-Scientific,
as per manufacturer’s instructions. Knock down effi-
ciency was then checked by real time PCR and Western
blotting. For HIF1α silencing: pre-designed siRNA was
used and transfected using Lipofectamine (Invitrogen) as
per manufacturer’s protocol and efficiency was checked by
Western blotting. For proliferation assay: cells were
counted before and after 48 hours of transfection, using
a hemocytometer.
RNA isolation, cDNA preparation and real time PCR
Cellular RNA was extracted from cell lines using TRIzol
(Sigma), according to manufacturer’s protocol. RNA qual-
ity was analyzed by A260/A280 absorbance and by electro-
phoresis on a 1.2% agarose formaldehyde gel. 3–4 μg of
total RNA was reverse transcribed into single stranded
DNA using cDNA preparation kit (Applied Biosystems,
USA). Commercially available Taqman gene expression
assay (Applied Biosystems, USA) was used for quantitating
mRNA levels of PKM2. β-actin was used as endogenous
control. Real time PCR was carried out on ABI Prism
7000 Sequence Detection System (Applied Biosystems).
ΔΔCt (Cycle threshold) method of relative quantification
was used to calculate fold change in gene expression by
SDS 1.1 RQ software (Applied Biosystems).
Cell lysate preparation, protein estimation and Western
blotting
Whole cell lysate was prepared by incubating cells, on
ice for 30 minutes, in buffer containing 50 mM Tris pH
7.2, 150 mM NaCl, 0.5% sodium deoxycholate, 10% gly-
cerol, 1% Triton X-100, 0.1% SDS, 1 mM DTT, 1 mM
PMSF, 5 mM NaF, 1 mM NaV, phosphatase inhibitor
cocktail (Sigma), 4 μg/ml aprotinin, 4 μg/ml leupeptin
and 4 μg/ml pepstatin (Sigma). The lysate was centri-
fuged at high speed in a cooling centrifuge (CM 12,
Remi, India) for 30 minutes and supernatant was col-
lected in pre-chilled fresh tubes. Protein concentration
was estimated using BCA method as per manufacturer
protocol (Thermo Scientific). Proteins were separated on
8% SDS-PAGE, transferred to nitrocellulose membrane
(mdi) at 4°C (wet transfer) and probed with primary
antibodies. Membrane was incubated with appropriate
secondary antibody for one hour at room temperature
and proteins were detected using Luminata forte
(Millipore). Primary antibodies used were: anti-HIF1α
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PKM2 (Tyr105), anti-AKT, anti-phospho-AKT, anti-
phosphoS6, anti-S6 protein and anti-β-actin (Cell Signalling
Technology).
PKM2 activity assay and glycerol gradient centrifugation
For activity, cells were lysed in buffer as described previ-
ously [12]. Activity was measured using NADH/lactate
dehydrogenase (LDH) coupled assay. Decrease in OD at
340 nm due to oxidation of NADH was monitored
using a double beam spectrophotometer (UV-1800,
Shimadzu). Reaction was started by adding 2 μg cell lys-
ate to mixture containing 50 mM Tris pH 7.5, 100 mM
KCl, 5 mM MgCl2, 1.25 mM ADP, 0.5 mM PEP, 0.28
mM NADH and 8 units of LDH. Specific activity per mg
of cell lysate was calculated as:
U=mg ¼ OD340=min
6:22mg lysate=ml reaction mixture
U/mg = specific enzyme activity per mg of protein.
OD340 = Change in absorbance due to oxidation of
NADH in one minute at 340 nm wavelength.
For glycerol gradient experiment, 500 μg of cell lysate
protein was loaded on the top of 11-25% glycerol gradi-
ent and centrifuged at 45000 rpm for 16 hours at 4°C in
SW55Ti rotor (Beckman Coulter) and rest of the pro-
cedure was followed as described [16].
Metabolites, glucose and lactate measurement
Metabolite extract was prepared from 20 million cells in 0.5
ml of chilled 90% ethanol containing 0.2% formic acid and
centrifuged at 15000 rpm in a refrigerated centrifuge. Super-
natant was dried using nitrogen flow and then reconstituted
in 0.2 ml of MilliQ water. PEP was assessed using NADH/
LDH coupled assay as mentioned above with 30 ng of re-
combinant PKM2. FBP was measured as described [51]. For
both FBP and PEP, concentration was determined against
standard curve. NADPH was analyzed using kit from
BioVision- USA, as per the manufacturer’s protocol. For glu-
cose and lactate: media was collected from wells; spun down
at high speed to remove any cell debris, deproteinized using
TCA, pH was adjusted between 7.0-7.5 and then glucose up-
take was analyzed using glucose assay kit (Sigma), according
to manufacturer’s protocol. Lactate and was analysed using
kit (BioVision, USA) as per manufacturer’s instructions. All
the measurements were normalized to cell numbers.
Ascorbate, NAC treatment and ROS analysis
Cells pretreated with or without ascorbate or NAC
(Sigma) were incubated with DCFH-DA for 30 minutes in
dark at 37°C, followed by insulin stimulation. Cells were
then washed with PBS, trypsinized and resuspended in 0.5ml PBS, kept on ice, in dark until ROS analysis by fluores-
cence spectrophotometry. Excitation and emission wave-
lengths used were 500 nm and 510 nm respectively.
Statistical analysis
Each experiment was performed in triplicate. All experi-
ments were repeated at least 3 times. Significance was
calculated using student’s t-test. P value less than 0.05
was considered statistically significant.
Additional files
Additional file 1: Figure S1. PKM2 is the predominant isoform in
H1299 and PC3 cell. PKM1 expression is negligibly low.
Additional file 2: Figure S2. Insulin up-regulated PKM2 expression in
H1299 and PC3 cells (C = Control, I = 100 nM insulin).
Additional file 3: Figure S3. PKM2 activity after different time points of
100 nM insulin treatment. Data is expressed as mean ± SE.
Additional file 4: Figure S4. Insulin treatement decreased PKM2
activity in H1299 and PC3 cells. Pretreatment with ROS scavenger- NAC,
reversed insulin-induced decrease in activity. Data is expressed as
mean ± SE. *P≤ 0.05.
Additional file 5: Figure S5. Glycerol gradient of cells pre-treated with
DMSO or 50 μM LY294002 or 20 nM rapamycin, followed by 100 nM
insulin treatment for 15 minutes.
Additional file 6: Figure S6. Representative Western blot showing no
change in phosphor-tyr-105-PKM2 upon insulin treatment (100 nM for 15
minutes) and inhibition with 50 μM LY294002 and 20 nM rapamycin, in
HepG2 cells.
Additional file 7: Figure S7. Immunoblot showing no change in
phosphor-tyr-105-PKM2 upon insulin treatment (100 nM for 15 minutes)
in H1299 and PC3 cells.
Additional file 8: Figure S8. Insulin treatement increase ROS in H1299
and PC3 cells. Pretreatment with 5 mM NAC decreased insulin-induced
ROS. Data is expressed as mean ± SE. *P ≤ 0.05.
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